Long-term follow-up
A total of 30 patients from the ITT population participated in the follow-up to Week 48: placebo (Mean fasting C-peptide was similar between the treatment groups at baseline and no notable changes were observed in any group. The mean (SD) change from baseline to Week 48 was − 0.02 (0.12) nmol/L in the placebo group, 0.02 (N/A) nmol/L in the dose A group, − 0.06 (0.17) nmol/L (SD:0.17) in the dose B group, and − 0.12 (0.15) nmol/L in the dose C group. There were no significant differences between groups.